Copyright Reports & Markets. All rights reserved.

Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Type
    • 1.3.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.3.2 Oral
    • 1.3.3 Subcutaneous Injection
    • 1.3.4 Others
  • 1.4 Market by Application
    • 1.4.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Application: 2020 VS 2026
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Others
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Perspective (2015-2026)
  • 2.2 Hereditary Transthyretin Amyloidosis (HATTR) Growth Trends by Regions
    • 2.2.1 Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Hereditary Transthyretin Amyloidosis (HATTR) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Hereditary Transthyretin Amyloidosis (HATTR) Industry Dynamic
    • 2.3.1 Hereditary Transthyretin Amyloidosis (HATTR) Market Trends
    • 2.3.2 Hereditary Transthyretin Amyloidosis (HATTR) Market Drivers
    • 2.3.3 Hereditary Transthyretin Amyloidosis (HATTR) Market Challenges
    • 2.3.4 Hereditary Transthyretin Amyloidosis (HATTR) Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Hereditary Transthyretin Amyloidosis (HATTR) Players by Market Size
    • 3.1.1 Global Top Hereditary Transthyretin Amyloidosis (HATTR) Players by Revenue (2015-2020)
    • 3.1.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Hereditary Transthyretin Amyloidosis (HATTR) Revenue
  • 3.4 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Concentration Ratio
    • 3.4.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Hereditary Transthyretin Amyloidosis (HATTR) Revenue in 2019
  • 3.5 Key Players Hereditary Transthyretin Amyloidosis (HATTR) Area Served
  • 3.6 Key Players Hereditary Transthyretin Amyloidosis (HATTR) Product Solution and Service
  • 3.7 Date of Enter into Hereditary Transthyretin Amyloidosis (HATTR) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Hereditary Transthyretin Amyloidosis (HATTR) Breakdown Data by Type

  • 4.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Historic Market Size by Type (2015-2020)
  • 4.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Type (2021-2026)

5 Hereditary Transthyretin Amyloidosis (HATTR) Breakdown Data by Application

  • 5.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Historic Market Size by Application (2015-2020)
  • 5.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2015-2026)
  • 6.2 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Type (2015-2020)
  • 6.3 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Application (2015-2020)
  • 6.4 North America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2015-2026)
  • 7.2 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Type (2015-2020)
  • 7.3 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Application (2015-2020)
  • 7.4 Europe Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2015-2026)
  • 8.2 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Type (2015-2020)
  • 8.3 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2015-2026)
  • 9.2 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Type (2015-2020)
  • 9.3 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Application (2015-2020)
  • 9.4 Latin America Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size (2015-2026)
  • 10.2 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa Hereditary Transthyretin Amyloidosis (HATTR) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 Pfizer
    • 11.1.1 Pfizer Company Details
    • 11.1.2 Pfizer Business Overview
    • 11.1.3 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.1.4 Pfizer Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020))
    • 11.1.5 Pfizer Recent Development
  • 11.2 Alnylam Pharmaceuticals
    • 11.2.1 Alnylam Pharmaceuticals Company Details
    • 11.2.2 Alnylam Pharmaceuticals Business Overview
    • 11.2.3 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.2.4 Alnylam Pharmaceuticals Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020)
    • 11.2.5 Alnylam Pharmaceuticals Recent Development
  • 11.3 Akcea Therapeutics
    • 11.3.1 Akcea Therapeutics Company Details
    • 11.3.2 Akcea Therapeutics Business Overview
    • 11.3.3 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.3.4 Akcea Therapeutics Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020)
    • 11.3.5 Akcea Therapeutics Recent Development
  • 11.4 Prothena
    • 11.4.1 Prothena Company Details
    • 11.4.2 Prothena Business Overview
    • 11.4.3 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.4.4 Prothena Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020)
    • 11.4.5 Prothena Recent Development
  • 11.5 Lonis Pharmaceuticals
    • 11.5.1 Lonis Pharmaceuticals Company Details
    • 11.5.2 Lonis Pharmaceuticals Business Overview
    • 11.5.3 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.5.4 Lonis Pharmaceuticals Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020)
    • 11.5.5 Lonis Pharmaceuticals Recent Development
  • 11.6 Eidos Therapeutics
    • 11.6.1 Eidos Therapeutics Company Details
    • 11.6.2 Eidos Therapeutics Business Overview
    • 11.6.3 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.6.4 Eidos Therapeutics Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020)
    • 11.6.5 Eidos Therapeutics Recent Development
  • 11.7 Corino Therapeutics Inc
    • 11.7.1 Corino Therapeutics Inc Company Details
    • 11.7.2 Corino Therapeutics Inc Business Overview
    • 11.7.3 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Introduction
    • 11.7.4 Corino Therapeutics Inc Revenue in Hereditary Transthyretin Amyloidosis (HATTR) Business (2015-2020)
    • 11.7.5 Corino Therapeutics Inc Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Hereditary Transthyretin Amyloidosis (HATTR) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hereditary Transthyretin Amyloidosis (HATTR) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Oral
    Subcutaneous Injection
    Others

    Market segment by Application, split into
    Hospital
    Clinic
    Others

    Based on regional and country-level analysis, the Hereditary Transthyretin Amyloidosis (HATTR) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global Hereditary Transthyretin Amyloidosis (HATTR) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Pfizer
    Alnylam Pharmaceuticals
    Akcea Therapeutics
    Prothena
    Lonis Pharmaceuticals
    Eidos Therapeutics

    Buy now